ENDRA Life Sciences Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
NDRA$4.77-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statements and Schedules
(a) List of documents filed as part of this report:
Financial Statements (see “Financial Statements and Supplementary Data” at Item 8 and incorporated herein by reference)
Financial Statement Schedules (Schedules to the Financial Statements have been omitted because the information required to be set forth therein is not applicable or is shown in the accompanying Financial Statements or notes thereto)
Exhibits
The following is a list of exhibits filed as part of this Annual Report:
| Exhibit · Filed · Incorporation by Reference | ||||
|---|---|---|---|---|
| Number · Exhibit Description · Herewith · Form · Exhibit · Filing Date | ||||
| 3.1 · Fourth Amended and Restated Certificate of Incorporation of the Company, as amended [Restated for SEC filing purposes only] · x | ||||
| 3.2 | Amended and Restated Bylaws of the Company | S-1 | 3.4 | 12/06/16 |
| 4.1 | Specimen Certificate representing shares of common stock of the Company | S-1 | 4.1 | 11/21/16 |
| 4.2 | Certificate of Designations of Series A Convertible Preferred Stock | 8-K | 4.1 | 12/11/19 |
| 4.3 | Form of Warrant issued in December 2019 Series A Convertible Preferred Stock Offering | 8-K | 4.2 | 12/11/19 |
| 4.4 | Certificate of Designations of Series B Convertible Preferred Stock | 8-K | 4.1 | 12/26/19 |
| 4.5 | Form of Warrant issued in December 2019 Series B Convertible Preferred Stock Offering | 8-K | 4.2 | 12/26/19 |
| 4.6 | Certificate of Designations of Series C Preferred Stock | 8-K | 3.1 | 09/27/22 |
| 4.7 | Form of Warrant issued in April 2023 Underwritten Public Offering | S-1 | 4.2 | 03/30/23 |
| 4.8 | Form of Underwriter’s Warrant issued in April 2023 Underwritten Public Offering | S-1/A | 4.3 | 04/18/23 |
| 4.9 | Form of Warrant Agency Agreement | S-1 | 4.4 | 03/30/23 |
| 4.10 | Form of Placement Agent Warrant | S-1 | 4.5 | 05/10/24 |
| 4.11 | Form of Series A Warrant | S-1 | 4.2 | 05/31/24 |
| 4.12 | Form of Series B Warrant | S-1 | 4.3 | 05/31/24 |
| 4.13 | Form of Pre-Funded Warrant | S-1 | 4.4 | 05/10/24 |
| 4.14 | Amendment to Series A Warrant | 10-Q | 3.8 | 08/14/24 |
| 4.15 | Amendment to Series B Warrant | 10-Q | 3.9 | 08/14/24 |
| 4.16 | Form of Common Warrant | 8-K | 4.1 | 10/15/25 |
| 4.17 | Form of Prefunded Warrant | 8-K | 4.2 | 10/15/25 |
| 4.18 | Form of Placement Agent Warrant | 8-K | 4.3 | 10/15/25 |
| 4.19 | Form of Advisory Warrant | 8-K | 4.4 | 10/15/25 |
| 4.20 | Description of Securities | 10-K | 4.12 | 03/30/22 |
| 10.1 | ENDRA Life Sciences Inc. 2016 Omnibus Incentive Plan* | S-1 | 10.4 | 12/06/16 |
| 10.2 | First Amendment to ENDRA Life Sciences Inc. 2016 Omnibus Incentive Plan* | DEF 14A | Appx. A | 05/10/18 |
| 10.3 | Second Amendment to ENDRA Life Sciences Inc. 2016 Omnibus Incentive Plan* | DEF 14A | Appx. B | 10/28/25 |
| 10.4 | Form of Stock Option Award under 2016 Omnibus Incentive Plan* | S-1 | 10.5 | 12/06/16 |
| 10.5 | Form of Restricted Stock Unit Award under 2016 Omnibus Incentive Plan* | S-1 | 10.6 | 12/06/16 |
| 10.6 | Non-Employee Director Compensation Policy, effective January 30, 2023* | 10-K | 10.6 | 03/16/23 |
| 10.7 | Form of Indemnification Agreement by and between the Company and each of its directors and executive officers* | S-1 | 10.8 | 11/21/16 |
| 10.8 | Amended and Restated Employment Agreement, dated May 12, 2017, by and between the Company and Michael Thornton* | 8-K | 10.2 | 05/12/17 | |
| 10.9 | First Amendment to Employment Agreement, dated December 27, 2019, by and between the Company and Michael Thornton* | 8-K | 10.2 | 12/27/19 | |
| 10.10 | Advisory Services Agreement, dated as of November 28, 2025 by and between the Company and Richard Jacroux | 8-K | 10.2 | 11/28/25 | |
| 10.11 | Employment Agreement, dated August 13, 2024, by and between the Company and Alexander Tokman* | 10-Q | 10.1 | 11/19/24 | |
| 10.12 | Consulting Agreement, dated as of November 28, 2025, by and between the Company and Michael Thornton | 8-K | 10.1 | 11/28/25 | |
| 10.13 | Gross Lease, dated January 1, 2015, between the Company and Green Court LLC | S-1 | 10.18 | 11/21/16 | |
| 10.14 | Amendment to Gross Lease, dated October 10, 2017, by and between the Company and Green Court LLC | 10-Q | 10.2 | 05/15/18 | |
| 10.15 | Second Amendment to Lease, dated March 15, 2021, by and between the Company and Green Court LLC | 10-K | 10.18 | 03/25/21 | |
| 10.16 | Third Amendment to Lease, dated December 1, 2024, by and between the Company and Green Court LLC | 10-K | 10.17 | 03/31/25 | |
| 10.17 | Consulting Agreement, dated October 17, 2023, by and between the Company and Alexander Tokman* | 10-K | 10.21 | 03/28/24 | |
| 10.18 | Amended and Restated Investment Management Agreement, dated as of September 17, 2025 by and between the Company and Arca Investment Management, LLC | 8-K | 10.3 | 10/15/25 | |
| 10.19 | Master Custody Service Agreement, dated as of July 16, 2025 by and between the Company and Anchorage Digital Bank, N.A. | S-1/A | 10.21 | 07/25/25 | |
| 10.20 | Securities Purchase Agreement, dated as of October 10, 2025, between ENDRA Life Sciences Inc. and the purchasers party thereto | 8-K | 10.1 | 10/15/25 | |
| 10.21 | Form of Registration Rights Agreement by and between ENDRA Life Sciences Inc. and the purchasers party thereto | 8-K | 10.2 | 10/15/25 | |
| 19.1 | ENDRA Life Sciences Inc. Insider Trading Policy | 10-K | 19.1 | 03/31/25 | |
| 21.1 | Subsidiaries of the Company | 10-K | 21.1 | 03/30/22 | |
| 23.1 | Consent of RBSM LLP, Independent Registered Public Accounting Firm (with respect to Forms S-3) | x | |||
| 23.2 | Consent of RBSM LLP, Independent Registered Public Accounting Firm (with respect to Forms S-8) | x | |||
| 24.1 | Power of Attorney (included on signature page) | x | |||
| 31.1 | Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 | x | |||
| 31.2 | Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 | x | |||
| 32.1 | Certification Pursuant to 18 U.S.C Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | x | |||
| 97 | Incentive-Based Compensation Recovery Policy | 10-K | 97 | 03/28/24 | |
| 101.INS | Inline XBRL Instance Document | x | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | x | |||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | x | |||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | x | |||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | x | |||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | x | |||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | ||||
| * | Indicates management compensatory plan, contract or arrangement. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.